Statistics from Altmetric.com
The first disease modifying treatments (DMT) of multiple sclerosis (MS) were introduced in the 1990s, and since then numerous new drugs have emerged. Tailoring the treatment in the individual patients with MS is difficult and requires detailed knowledge of the efficacy and risks of all available preparations. Comparing different drugs alone from their effects over placebo or first-generation drugs in the randomised controlled trials is problematic because these studies have been applied to different MS populations, and although there has been a certain harmony in inclusion criteria between such studies, the natural selection of study candidates from the different background MS populations may vary considerably. The many available DMTs enable preparation …
Contributors NK-H solely authored this editorial.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests NK-H has within 2 years received support for participation in congresses and symposia by SG.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.